Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.
The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects.
Migraine Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Migraine pipeline drugs market are 5-Hydroxytryptamine Receptor 1D, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide, Calcitonin Gene Related Peptide Type 1 Receptor, Gamma-Aminobutyric Acid Type A Receptor Subunit, and 5-Hydroxytryptamine Receptor 2A.
Migraine Pipeline Drugs Market Analysis, by Targets
For more Migraine pipeline drugs market target insights, download a free report sample
Migraine Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the Migraine pipeline drugs market are 5-Hydroxytryptamine Receptor 1D Agonist, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Pituitary Adenylate Cyclase Activating Polypeptide Inhibitor.
Migraine Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Migraine pipeline drugs market, download a free report sample
Migraine Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Migraine pipeline drugs market are oral, subcutaneous, intravenous, nasal, intramuscular, and transmucosal.
Migraine Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Migraine pipeline drugs market, download a free report sample
Migraine Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Migraine pipeline drugs market are Small Molecule, Monoclonal Antibody, Protein, Peptide, Recombinant Protein, and Synthetic Peptide.
Migraine Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Migraine pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Migraine pipeline drugs market are Klaria Pharma Holding AB, Biohaven Pharmaceutical Holding Company Ltd, Eli Lilly and Co, H. Lundbeck AS, Ceruvia Lifesciences LLC, and AbbVie Inc.
Migraine Pipeline Drugs Market Analysis, by Companies
To know more about the Migraine pipeline drugs market companies, download a free report sample
Migraine Pipeline Drugs Market Report Overview
Key Targets | 5-Hydroxytryptamine Receptor 1D, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide, Calcitonin Gene Related Peptide Type 1 Receptor, Gamma-Aminobutyric Acid Type A Receptor Subunit, and 5-Hydroxytryptamine Receptor 2A |
Key Mechanism of Actions | 5-Hydroxytryptamine Receptor 1D Agonist, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Pituitary Adenylate Cyclase Activating Polypeptide Inhibitor |
Key Routes of Administration | Oral, Subcutaneous, Intravenous, Nasal, Intramuscular, and Transmucosal |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Protein, Peptide, Recombinant Protein, and Synthetic Peptide |
Key Companies | Klaria Pharma Holding AB, Biohaven Pharmaceutical Holding Company Ltd, Eli Lilly and Co, H. Lundbeck AS, Ceruvia Lifesciences LLC, and AbbVie Inc. |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of migraine.
- Reviews of pipeline therapeutics for Migraine by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews key companies involved in Migraine therapeutics and enlists all their major and minor projects.
- Evaluation of Migraine therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Migraine.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Migraine.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Migraine pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AbbVie Inc
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Acherx LLC
AEON Biopharma Inc
AgoneX Biopharmaceuticals Inc
Allodynic Therapeutics LLC
Amgen Inc
Amneal Pharmaceuticals Inc
AOBiome LLC
Arovella Therapeutics Ltd
Asarina Pharma AB
AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Benuvia Therapeutics Inc
Better Life Pharmaceuticals Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Cerecin Pte Ltd
Ceruvia Lifesciences LLC
Charleston Laboratories Inc
Citragen Pharmaceuticals Inc
Corium Inc
Crossject SA
Crystec Ltd
Curatis AG
DelNova Inc
Dr. Reddy's Laboratories Ltd
Eli Lilly and Co
Epalex Corp
Exxel Pharma Inc
Gubra ApS
H. Lundbeck AS
HEC Pharma Co Ltd
IACTA Pharmaceuticals Inc
InStar Technologies AS
IntelGenx Corp
Invisio Ltd
Ionis Pharmaceuticals Inc
Kallyope Inc
Kissei Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Lateral Pharma Pty Ltd
MannKind Corp
Merck & Co Inc
Microgen
Mydecine Innovations Group Inc
NAL Pharmaceuticals Ltd
NeurAxon Pharma Inc
NutriBand Inc
OWP Pharmaceuticals Inc
Panaxia Pharmaceutical Industries Ltd
PassPort Technologies Inc (USA)
Pharmnovo AB
Pherin Pharmaceuticals Inc
Pulmatrix Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
RAFT Pharmaceuticals
Revance Therapeutics Inc
Saniona AB
Satsuma Pharmaceuticals Inc
Seurat Therapeutics Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Sorrento Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Tremeau Pharmaceuticals Inc
Trevena Inc
Trigemina Inc
TrioxBio Inc
Vaxxinity Inc
Xoc Pharmaceuticals Inc
Zosano Pharma Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Migraine pipeline drugs market?
Some of the key targets in the Migraine pipeline drugs market are the 5-Hydroxytryptamine Receptor 1D, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide, Calcitonin Gene Related Peptide Type 1 Receptor, Gamma-Aminobutyric Acid Type A Receptor Subunit, and 5-Hydroxytryptamine Receptor 2A.
-
What are the key mechanisms of action in the Migraine pipeline drugs market?
Some of the key mechanisms of action in the Migraine pipeline drugs market are 5-Hydroxytryptamine Receptor 1D Agonist, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Pituitary Adenylate Cyclase Activating Polypeptide Inhibitor.
-
What are the key routes of administration in the Migraine pipeline drugs market?
The key routes of administration in the Migraine pipeline drugs market are oral, subcutaneous, intravenous, nasal, intramuscular, and transmucosal.
-
What are the key molecule types in the Migraine pipeline drugs market?
The molecule types in the Migraine pipeline drugs market are Small Molecule, Monoclonal Antibody, Protein, Peptide, Recombinant Protein, and Synthetic Peptide.
-
Which are the leading companies in the Migraine pipeline drugs market?
Some of the leading companies in the Migraine pipeline drugs market are Klaria Pharma Holding AB, Biohaven Pharmaceutical Holding Company Ltd, Eli Lilly and Co, H. Lundbeck AS, Ceruvia Lifesciences LLC, and AbbVie Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.